1 |
KAZEMIFARD N, SADEGHI A, VARAMINIAN B, et al. Circulating tumor DNA applications in monitoring the treatment of metastatic colorectal cancer patients[J]. Gastroenterol Hepatol Bed Bench, 2019,12():S14-S21.
|
2 |
BETTEGOWDA C, SAUSEN M, LEARY R J, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014,6(224):224ra24.
|
3 |
SAAVEDRA K P, BREBI P M, ROA J C. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix[J]. Clin Epigenetics, 2012,4(1):13. doi:10.1186/1868-7083-4-13
doi: 10.1186/1868-7083-4-13
|
4 |
中国抗癌协会妇科肿瘤专业委员会. 阴道恶性肿瘤诊断与治疗指南(2021年版)[J].中国癌症杂志, 2021,31:546-60.
|
5 |
CAMPITELLI M, JEANNOT E, PETER M, et al. Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients[J]. PLoS One, 2012,7(8):e43393. doi:10.1371/journal.pone.0043393
doi: 10.1371/journal.pone.0043393
|
6 |
CAROW K, GöLITZ M, WOLF M, et al. Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA[J]. Int J Mol Sci, 2017,18(10):2032. doi:10.3390/ijms18102032
doi: 10.3390/ijms18102032
|
7 |
SIVARS L, PALSDOTTIR K, CRONA GUTERSTAM Y, et al. The current status of cell-free human papillomavirus DNA as a biomarker in cervical cancer and other HPV-associated tumors: A review[J]. Int J Cancer, 2023,152(11):2232,2242. doi:10.1002/ijc.34333
doi: 10.1002/ijc.34333
|
8 |
BøNLøKKE S, STOUGAARD M, SORENSEN B S, et al. The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients[J]. Cells, 2022,11(14):2170. doi:10.3390/cells11142170
doi: 10.3390/cells11142170
|
9 |
SIVARS L, HELLMAN K, CRONA GUTERSTAM Y, et al. Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer[J]. Gynecol Oncol, 2022,167(1):107-114. doi:10.1016/j.ygyno.2022.07.028
doi: 10.1016/j.ygyno.2022.07.028
|
10 |
JEANNOT E, LATOUCHE A, BONNEAU C, et al. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer[J]. Clin Cancer Res, 2021,27(21):5869-5877. doi:10.1158/1078-0432.ccr-21-0625
doi: 10.1158/1078-0432.ccr-21-0625
|
11 |
CABEL L, BONNEAU C, BERNARD-TESSIER A, et al. HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer[J]. ESMO Open,2021,6(3):100154. doi:10.1016/j.esmoop.2021.100154
doi: 10.1016/j.esmoop.2021.100154
|
12 |
CHEUNG T H, YIM S F, YU M Y, et al. Liquid biopsy of HPV DNA in cervical cancer[J]. J Clin Virol, 2019,114:32-36. doi:10.1016/j.jcv.2019.03.005
doi: 10.1016/j.jcv.2019.03.005
|
13 |
辇伟奇,于津浦,袁响林,等. ctDNA高通量测序临床实践专家共识(2022年版)[J].中国癌症防治杂志, 2022,14(3):240-252.
|
14 |
SPELLMAN P T, GRAY J W. Detecting cancer by monitoring circulating tumor DNA[J]. Nat Med, 2014,20(5):474-475. doi:10.1038/nm.3564
doi: 10.1038/nm.3564
|
15 |
FERRIER S T, TSERING T, SADEGHI N, et al. Blood and saliva-derived ctDNA is a marker of residual disease after treatment and correlates with recurrence in human papillomavirus-associated head and neck cancer[J]. Cancer Med, 2023,12(15):15777-15787. doi:10.1002/cam4.6191
doi: 10.1002/cam4.6191
|
16 |
JEANNOT E, BECETTE V, CAMPITELLI M, et al. Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma[J]. J Pathol Clin Res, 2016,2(4):201-209. doi:10.1002/cjp2.47
doi: 10.1002/cjp2.47
|
17 |
BARBANY G, ARTHUR C, LIEDéN A, et al. Cell-free tumour DNA testing for early detection of cancer - a potential future tool[J]. J Intern Med, 2019,286(2):118-136. doi:10.1111/joim.12897
doi: 10.1111/joim.12897
|
18 |
MOSS J, MAGENHEIM J, NEIMAN D, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease[J]. Nat Commun, 2018,9(1):5068. doi:10.1038/s41467-018-07466-6
doi: 10.1038/s41467-018-07466-6
|
19 |
ROSTAMI A, LAMBIE M, YU C W, et al. Senescence, Necrosis, and Apoptosis Govern Circulating Cell-free DNA Release Kinetics[J]. Cell Rep, 2020,31(13):107830. doi:10.1016/j.celrep.2020.107830
doi: 10.1016/j.celrep.2020.107830
|
20 |
BROUTET N, JERONIMO J, KUMAR S, et al. Implementation research to accelerate scale-up of national screen and treat strategies towards the elimination of cervical cancer[J]. Prev Med,2022,155:106906. doi:10.1016/j.ypmed.2021.106906
doi: 10.1016/j.ypmed.2021.106906
|
21 |
冯同富. 宫颈癌筛查策略的变迁及思考[J]. 实用医学杂志,2022,38(15):1865-1871. doi:10.3969/j.issn.1006-5725.2022.15.004
doi: 10.3969/j.issn.1006-5725.2022.15.004
|
22 |
缪华章, 吴云涛,朱颖贤. 2017-2019年广东省农村适龄妇女宫颈癌和乳腺癌筛查结果和成本效果分析[J]. 实用医学杂志, 2023,39(13):1709-1713. doi:10.3969/j.issn.1006-5725.2023.13.020
doi: 10.3969/j.issn.1006-5725.2023.13.020
|
23 |
PHALLEN J, SAUSEN M, ADLEFF V, et al. Direct detection of early-stage cancers using circulating tumor DNA[J]. Sci Transl Med, 2017,9(403):eaan2415. doi:10.1126/scitranslmed.aan2415
doi: 10.1126/scitranslmed.aan2415
|
24 |
GALATI L, COMBES J D, LE CALVEZ-KELM F, et al. Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay[J]. Microbiol Spectr, 2022,10(2):e0148021. doi:10.1128/spectrum.01480-21
doi: 10.1128/spectrum.01480-21
|
25 |
谢玲玲,林荣春,林仲秋. 《2021.2 NCCN外阴鳞癌临床实践指南》解读[J]. 中国实用妇科与产科杂志, 2020,36(12):1172-1176.
|
26 |
RASMUSSEN C L, SAND F L, HOFFMANN FREDERIKSEN M, et al. Does HPV status influence survival after vulvar cancer?[J]. Int J Cancer, 2018,142(6):1158-1165. doi:10.1002/ijc.31139
doi: 10.1002/ijc.31139
|
27 |
SASTRE-GARAU X, DIOP M, MARTIN F, et al. A NGS-based Blood Test For the Diagnosis of Invasive HPV-associated Carcinomas with Extensive Viral Genomic Characterization[J]. Clin Cancer Res, 2021,27(19):5307-5316. doi:10.1158/1078-0432.ccr-21-0293
doi: 10.1158/1078-0432.ccr-21-0293
|